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Abstract
Background: This trial compares the efficacy of administering a combination of ezetimibe plus
fenofibrate as an alternative to statin monotherapy for the treatment of dyslipidemia. In this
randomized, unblinded crossover study, 43 patients with documented hypercholesterolemia
requiring pharmacotherapy were randomized to receive six weeks of either a combination of 10
mg of ezetimibe plus 160 mg of fenofibrate (combination) or 10 mg of atorvastatin monotherapy
(atorvastatin). The primary endpoint was the percentage reduction of low-density lipoprotein
cholesterol (LDL-C).
Results: LDL-C decreased by 34.6% with the combination therapy versus 36.7% with atorvastatin
monotherapy. The difference between the two groups was not statistically significant (p = 0.46).
Both study interventions provided similar improvements in total cholesterol (-25.1% with
combination versus -24.6% with atorvastatin, p = 0.806) and high-density lipoproteins (+10.0% with
combination versus +8.9% with atorvastatin, p = 0.778). Combination therapy showed a trend
towards a greater reduction in triglycerides (-25.4% with combination versus -14.5% with
atorvastatin, p = 0.079), although there was no significant difference between the two study
interventions in terms of the improvement in the TC:HDL ratio (-29.0% with combination versus
-28.7% with atorvastatin, p = 0.904).
Conclusions: The combination of ezetimibe plus fenofibrate appeared to produce nearly identical
alterations in serum lipoprotein levels when compared to monotherapy with 10 mg of atorvastatin.
Daily treatment with the combination of ezetimibe plus fenofibrate is an acceptable alternative to
atorvastatin for the treatment of dyslipidemia in patients who are intolerant of statins.
Background
3-hydroxy-3-methylgluatryl-coenzyme A reductase inhib-
itors (statins) are the most potent and frequently used
drugs for the treatment of hypercholesterolemia. Statin
therapy has been shown to reduce the rate of major vascu-
lar events in patients with established vascular disease [1],
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ment of dyslipidemia in such individuals [2]. The with-
drawal of cerivastatin from the U.S. market on August 8,
2001, however, has prompted concern on the part of phy-
sicians and patients regarding the safety of statins.
Although statins are well tolerated by the majority of
patients, known side effects include transaminitis, myal-
gias, myositis and very rarely, rhabdomyolysis [3].
Whether perceived or real, concerns over these potential
side effects can result in the discontinuation of statin ther-
apy in a significant minority of patients [4]. Until recently,
however, there have not been any safe, effective and well-
tolerated alternatives to statin therapy for the manage-
ment of dyslipidemia in patients with vascular disease.
Ezetimibe is a novel cholesterol absorption inhibitor that
prevents cholesterol absorption by inhibiting the trans-
port of cholesterol across the intestinal wall. Treatment
with ezetimibe as monotherapy results in a reduction of
LDL cholesterol (LDL-C) by approximately 18% [5], and
has been shown to be well tolerated, with a safety profile
similar to that of placebo [6,7]. When compared to the
effect of statins on the lowering of LDL-C, however,
ezetimibe would appear to provide only a modest benefit
[8].
Fenofibrate is a fibric acid derivative that binds to peroxi-
some proliferator-activated receptor alpha and alters lipo-
protein synthesis [9]. Treatment with fenofibrate
monotherapy has also been proven to provide modest
reductions in LDL-C, and may also be an effective thera-
peutic option for patients who are intolerant of statins
[10]. And while both ezetimibe and fenofibrate each pro-
vide only modest reductions in LDL-C when used as mon-
otherapy, the co-administration of ezetimibe with
fenofibrate has been shown to produce significantly
greater reductions in LDL-C than with either drug alone,
suggesting that the combination may be an effective sec-
ond-line therapeutic option in patients who are intolerant
of statins [9]. The safety of the combination has been
shown both in short and long-term trials. Farnier et al. in
2005 demonstrated the safety and efficacy of the combi-
nation in a cohort with mixed hyperlipidemia over a
twelve-week period [11]. More recently, McKenney et al.
demonstrated that the combination of fenofibrate and
ezetimibe, delivered over 48 weeks, was both well-toler-
ated and efficacious, in comparison with fenofibrate
alone [12].
To date, we are not aware of any study which has com-
pared the effectiveness and tolerability of the co-adminis-
tration of ezetimibe and fenofibrate with statin therapy in
patients with hypercholesterolemia. Accordingly, this
study was designed to test the hypothesis that the combi-
nation of ezetimibe and fenofibrate is an effective alterna-
tive to statin use for statin-intolerant patients with
hypercholesterolemia and vascular disease.
Results
Study design
Between January 2005 and February 2006, 48 patients
were evaluated for eligibility and 45 patients deemed eli-
gible (Figure 1). Two patients withdrew prior to randomi-
zation. Twenty-three patients were initially randomized to
start with the combination and twenty patients were ran-
domized to initiate therapy with atorvastatin. A further
two patients subsequently declined further participation
in the study; both were from the combination group. 41
patients therefore completed the study; 21 in the initial
combination group and 20 in the initial atorvastatin
group. The reasons for early discontinuation of the study
were primarily withdrawal of consent and subsequent loss
to follow-up. The baseline demographic and laboratory
characteristics are listed in Table 1. The two groups were
similar with respect to all baseline characteristics except
for age - the patients who began the study with the com-
bination therapy group were somewhat younger than
those who began the study with atorvastatin alone. Nearly
two-thirds of all patients had been on prior lipid-lowering
therapy, all with statins, which were discontinued prior to
the study washout period.
Lipid profile effects
During the six weeks of treatment, LDL-C decreased by
34.6% (p < 0.001) with the combination therapy versus
36.7% (p < 0.001) with atorvastatin monotherapy (Figure
2 and Table 2). The difference between the two interven-
tions was not statistically significant (2.1 +/- 2.8%, p =
0.46). Both study interventions provided similar improve-
ments in TC (-25.1%, p < 0.001 with combination therapy
versus -24.6%, p < 0.001 with atorvastatin monotherapy,
p = 0.806 for difference between the two groups) and
HDL-C (10.0%, p = 0.002 with combination therapy ver-
sus 8.9%, p = 0.006 with atorvastatin monotherapy, p =
0.778 for difference between the two groups). Combina-
tion therapy showed a non-significant trend towards a
greater reduction in triglycerides (-25.4%, p < 0.001 with
combination therapy versus -14.5%, p = 0.002 with ator-
vastatin monotherapy, p = 0.079 for difference between
the two groups), though there was no significant differ-
ence between the two study interventions in terms of the
improvement in the TC:HDL ratio (-29.0%, p < 0.001
with combination therapy versus -28.7%, p < 0.001 with
atorvastatin monotherapy, p = 0.904 for difference
between the two groups).
The apolipoprotein A and B levels before and after each
six-week treatment period were also examined. While
there was no significant change in apolipoprotein A levels
with atorvastatin monotherapy (+1.5%, p = 0.493), therePage 2 of 8
(page number not for citation purposes)
Lipids in Health and Disease 2009, 8:56 http://www.lipidworld.com/content/8/1/56was a small, albeit statistically significant increase in apol-
ipoprotein A levels in the combination therapy group
(+4.5%, p = 0.041). There was, however, no significant
difference on apolipoprotein A levels (3.04 +/- 2.9%, p =
0.295) between the two treatment groups. Apolipoprotein
B levels declined in both treatment groups (-31.8%, p <
0.001 with combination therapy versus -29.8%, p < 0.001
with atorvastatin monotherapy). There was no significant
difference in change of apolipoprotein B level between the
two groups (-1.99 +/- 2.3%, p = 0.392).
Other results
The level of hsCRP did not show significant change with
either combination therapy or atorvastatin monotherapy.
In the combination therapy group there was a non-signif-
icant decrease in hsCRP of 0.1 mmol/L (range of -1.0 to
0.5, p = 0.49). The median change in hsCRP in the atorv-
astatin monotherapy group was a decrease of 0.1 mmol/L
with a range from -0.8 mmol/L to 0.8 mmol/L of change,
with p = 0.75. As a result, there was no significant differ-
ence in the change in hsCRP between the two groups
(decrease of 0.1 mmol/L overall, with range -1.5 to 1.2, p
= 0.99).
Adverse events
No serious adverse events occurred during the study. One
patient, who was randomized to begin with the combina-
tion therapy, noted dizziness and headache while on
combination therapy and declined further participation
after the first phase of the study (i.e. after completion of
the combination therapy). Two patients complained of
constipation while on combination therapy, whereas one
complained of constipation while on atorvastatin mono-
therapy. Two patients complained of abdominal cramp-
ing while on combination therapy, and one of these
patients stopped the combination therapy twelve days
Table 1: Baseline Demographics Mean (SD) or %
Atorvastatin Combination
Age (years) 67.09 (9.668) 60.50 (9.561)
Male Sex 85 73.9
Coronary artery disease (%) 60 43.5
Angina 40 39.1
Previous Myocardial Infarction 35 13
Previous PCI 40 21.7
Previous CABG 15 21.7
Cerebrovascular Disease (%) 45 60.9
Peripheral Vascular Disease (%) 0 4.3
Lipid Parameters
Total Cholesterol (mmol/L) 5.69 (0.78) 5.98 (0.91)
Low density lipoprotein (mmol/L) 3.58 (0.53) 3.91 (0.71)
High density lipoprotein (mmol/L) 1.31 (0.28) 1.44 (0.20)
Triglycerides (mmol/L) 1.75 (0.70) 1.35 (0.49)
TC/HDL Ratio 4.49 (0.97) 4.20 (0.65)
Smoking Status (%)
Never Smoked 25 34.8
Previous Smoker 70 52.2
Current Smoker 5 13
Diabetes Mellitus (%) 10 30.4
Body Mass Index (kg/m2) 27.8 (3.50) 28.2 (5.43)
Weight (kg) 83.2 (12.80) 82.2 (17.82)
History of Hypertension (%) 60 65.2
Systolic Blood Pressure (mmHg) 128.4 (16.14) 121.4 (15.88)
Diastolic Blood Pressure (mmHg) 73.2 (8.57) 72.9 (11.68)
Mean hsCRP 3.62 (3.59) 2.91 (4.18)
Antithrombotic Therapy # (%) 19 (95) 23 (100)
Previous Lipid-Lowering Therapy # (%) 12 (60) 15 (65.2)
ACE-I/ATII Therapy # (%) 15 (75.0) 20 (87.0)Page 3 of 8
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Enrollment and OutcomesFigure 1
Enrollment and Outcomes.
Lipids in Health and Disease 2009, 8:56 http://www.lipidworld.com/content/8/1/56early as a result. Two patients complained of dizziness and
postural changes while on atorvastatin monotherapy, but
these were felt to be secondary to ACE inhibitor use and
resolved with dosage adjustment of the ACE inhibitor.
None of the patients in this study developed elevations in
serum aminotransferase levels (alanine aminotransferase
[ALT] or aspartate aminotransferase [AST]), as defined by
an aminotransferase elevation >3 times the upper limit of
normal [13] at any time throughout the duration of the
study. None of the patients experienced symptomatic
myopathy, as defined by complaints referable to skeletal
muscle, including myalgias (muscle pain), weakness (by
complaint or objective testing) and cramps [14], at any
time throughout the duration of the study. However,
there were 23 instances of asymptomatic myopathy (as
defined by CK elevations without symptoms or objective
evidence of weakness [14]) in 14 subjects that were asso-
ciated with mild (as defined by CK levels greater than nor-
mal, but less than 10 times the upper limit of normal
[14]) CK elevation. Seven of these instances occurred
while subjects were not taking any antidyslipidemic med-
ication (i.e. they were in the washout phase). Seven
instances occurred while subjects were taking combina-
tion therapy, and nine instances occurred while subjects
were taking atorvastatin monotherapy. There were no
instances of asymptomatic myopathy that were associated
with moderate (as defined by CK levels equal to or greater
than 10 times the upper limit of normal but less than 50
times the upper limit of normal [14]) or severe (as defined
by CK levels equal to or greater than 50 times the upper
limit of normal [14]) CK elevation.
Discussion
The combination of ezetimibe plus fenofibrate in this
study produced nearly identical alterations in serum lipo-
protein levels when compared to monotherapy with 10
mg of atorvastatin. Combination therapy with ezetimibe
plus fenofibrate did produce small, albeit statistically sig-
nificant increases in apolipoprotein A levels, while none
were observed with atorvastatin monotherapy. While
both combination therapy and atorvastatin monotherapy
significantly decreased triglycerides levels, combination
therapy showed a trend towards a greater reduction in trig-
lycerides than with atorvastatin monotherapy. Both treat-
ments were generally well tolerated and there were no
clinically important increases in either transaminitis or
myopathy.
It is important, however, to emphasize that atorvastatin
was delivered at a low dose in our study, and that one
would expect more significant effects on TC, LDL-C and
TC:HDL ratio with the utilization of higher doses of ator-
vastatin, as is the case in the contemporary management
of dyslipidemia in patients with cardiovascular disease
[2]. In contrast, the doses of fenofibrate and ezetimibe
used in this study are the maximum approved doses of
these agents and further titration is not possible.
Moreover, in contrast to statin therapy, which has an over-
whelming burden of evidence to support its efficacy for
the prevention of cardiovascular events, neither ezetimibe
[15], nor fenofibrate [16], either alone or in combination
has been shown to produce similar reductions in cardio-
vascular morbidity or mortality. Accordingly statin ther-
apy is, and should remain, first line therapy for the
Table 2: Baseline and Changes from Baseline in Total Cholesterol, LDL-C, HDL-C, Triglycerides, TC:HDL Ratio, Apo A and Apo B 
after 6 Weeks of Treatment with either the Combination of Ezetimibe plus Fenofibrate or Atorvastatin Monotherapy
Ezetimibe plus Fenofibrate Atorvastatin Monotherapy
Baseline 6 Weeks % Change p Value Baseline 6 Weeks % Change p Value % Difference p Value
Total Chol (mmol/L) 5.9 4.4 -25.1 < 0.001 5.8 4.4 -24.6 < 0.001 -0.4 0.806
LDL-C (mmol/L) 3.8 2.4 -34.6 < 0.001 3.7 2.3 -36.7 < 0.001 2.1 0.46
HDL-C (mmol/L) 1.4 1.5 10.0 0.002 1.3 1.5 8.9 0.006 1.1 0.778
Triglycerides 
(mmol/L)
1.5 1.0 -25.4 < 0.001 1.6 1.4 -14.5 0.002 -11.0 0.079
TC:HDL Ratio 4.3 3.0 -29.0 < 0.001 4.4 3.1 -28.7 < 0.001 -0.2 0.904
Apo A 1.27 1.32 4.5 0.041 1.29 1.30 1.5 0.493 3.04 0.295
Apo B 1.21 0.82 -31.8 < 0.001 1.19 0.82 -29.8 < 0.001 -1.99 0.392
Comparison of Ezetimibe Plus Fenofibrate Versus Atorvasta-tin On LDL-C Reduction Over TimeFigure 2
Comparison of Ezetimibe Plus Fenofibrate Versus 









ezetrol plus fenofibrate 




Per iod II Per iod I 
6 10 16 
Washout 
Weeks in Study Page 5 of 8
(page number not for citation purposes)
Lipids in Health and Disease 2009, 8:56 http://www.lipidworld.com/content/8/1/56management of dyslipidemia in patients with cardiovas-
cular disease despite of the results of this study. Further,
statin therapy, because it requires only a single daily pill,
may be associated with higher degrees of patient adher-
ence to therapy than combination therapy. Combination
therapies are also more expensive than monotherapies -
cost may therefore also limit the utility of the combina-
tion therapy outside of the clinical trial setting.
Nevertheless, a significant minority of patients discon-
tinue statin therapy due to concerns over side effects,
whether these concerns are perceived or real. For instance,
in the PRIMO Study [4], between 5% and 18% of patients
experienced muscular symptoms while receiving high-
dosage statin therapy in an outpatient setting. As a conse-
quence, many of these patients may elect to discontinue
treatment with statin medication, and for them, an alter-
native to statin therapy would be useful, despite the afore-
mentioned advantages of statin monotherapy.
Based upon the results of the present study, the substitu-
tion of atorvastatin with the combination of ezetimibe
and fenofibrate would seem to be a reasonable option in
such patients who are intolerant of statin therapy, recog-
nizing that the combination of ezetimibe plus fenofibrate
has not been determined to prevent cardiovascular disease
in randomized controlled trials. For instance, in the
ENHANCE Trial, treatment with ezetimibe as mono-
therapy resulted in a reduction of LDL cholesterol (LDL-
C) by 16.5% [15], but did not significantly reduce pro-
gression of carotid atherosclerosis, as determined by
measurement of carotid intimal medial thickening. In the
FIELD Study, treatment with fenofibrate as monotherapy
resulted in a reduction of LDL cholesterol (LDL-C) by
approximately 14.7% compared to those patients who did
not start other lipid-lowering therapy [16], but did not sig-
nificantly reduce the risk of coronary events.
Whether a 15-20% reduction in LDL-C is enough to sig-
nificantly reduce the risk of cardiovascular also remains to
be seen. For instance, in the ALLHAT-LLT Trial, no signif-
icant difference in all-cause mortality or combined fatal
and nonfatal CHD was demonstrated between the pravas-
tatin and the usual care groups [17]. This was in the con-
text of a 16.7% differential in LDL-C between the two
treatment groups.
And while more modest reductions in LDL-C with either
ezetimibe or fenofibrate monotherapy may not be suffi-
cient to realize clinically important reductions in cardio-
vascular outcomes, the more aggressive approach of
combining ezetimibe and fenofibrate may be more effec-
tive in achieving LDL-C lowering and clinically important
and statistically significant differences in cardiovascular
outcomes. Based on the data from the meta-analysis,
which was performed by the Cholesterol Treatment Trial-
ists' (CTC) Collaborators, a reduction of LDL-C by the 1.4
mmol/L that was achieved with the combination of
ezetimibe plus fenofibrate would result in a reduction in
major coronary events by 32% [18]. As such, the combi-
nation may have the potential to realize similar results to
the Heart Protection Study [19], which achieved a signifi-
cant 24% reduction in major adverse cardiac events with
a 29% reduction in LDL-C.
Limitations
This study was not blinded or powered to detect differ-
ences in clinical outcomes between the two treatment
groups. Prior use of study medications and the short dura-
tion of therapy in this study may also have minimized
potential safety and tolerability issues - six weeks on each
therapy may not have been enough time to detect signifi-
cant differences in adverse effects of each medication.
Accordingly, the consequences of long-term use of combi-
nation therapy with ezetimibe plus fenofibrate are not
known and would require the completion of larger, ran-
domised and blinded studies.
Conclusions
The combination of ezetimibe 10 mg daily plus fenofi-
brate 160 mg daily appeared to produce nearly identical
alterations in serum lipoprotein levels when compared to
monotherapy with 10 mg of atorvastatin. Daily treatment
with the combination of ezetimibe plus fenofibrate is an
acceptable alternative to atorvastatin for the treatment of
dyslipidemia in patients who are intolerant of statins.
Methods
Research design
Men and women between the ages of 18 and 85 were
recruited from the Southeastern Ontario Vascular Disease
Prevention and Research Centre, located at Queen's Uni-
versity in Kingston, Ontario. Patients were eligible for the
study if they had documented hypercholesterolemia, with
an LDL-C≥3.0 mmol/L. Patients were excluded if they had
a history of hepatic disease (AST or ALT ≥ 3 ULN), eleva-
tion of creatine kinase (CK ≥ 3 ULN), uncontrolled diabe-
tes (HbA1c ≥ 10%), intolerance or hypersensitivity to
statins, fibric acid derivatives or ezetimibe, were pregnant
or breastfeeding, had a history of excessive alcohol use,
were enrolled in another study, or had an acute coronary
syndrome or stroke within 6 weeks of enrolment. All
patients provided written informed consent. This study
was approved by the Research Ethics Board at Queen's
University in Kingston, Ontario.
The study design was that of an unblinded but rand-
omized cross-over study. Patients who were previously on
lipid-lowering therapy underwent a 4-week washout
period before entry into the study. Prior to randomiza-Page 6 of 8
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recorded. Blood work was drawn after a 14 hour fast, and
analyzed for the following constituents: lipid profile
(total cholesterol (TC), low-density lipoprotein choles-
terol (LDL-C), high density lipoprotein cholesterol (HDL-
C), triglycerides (TG), total cholesterol to high density
lipoprotein ratio (TC/HDL), apolipoprotein A and apoli-
poprotein B), high sensitivity C-reactive protein (hsCRP),
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), bilirubin, creat-
ine kinase (CK), fasting glucose and HbA1c (for patients
with diabetes), electrolytes, and creatinine. Total choles-
terol and triglyceride concentrations were measured enyz-
matically. All enzymatic lipid testing was performed on
the Roche Modular (Roche Diagnostics Canada, Canada).
LDL-C was calculated using the Friedewald formula
applied to the values measured.
Patients were then randomly assigned to receive either a
combination of 10 mg of ezetimibe plus 160 mg of fenof-
ibrate (combination) or 10 mg of atorvastatin mono-
therapy (atorvastatin) for 6 weeks. Patients were not
blinded to treatment allocation. After completion of the
first phase of the study, patients underwent a 4-week
washout period. The patients were then switched to the
other regimen for another 6 weeks. Following this phase,
patients had their involvement in the study concluded,
and were placed back on statin therapy for their hypercho-
lesterolemia, and post-study usual follow-up was
arranged with their regular physicians. After the end of
each treatment regimen and washout period, patients
returned to clinic for repeat measurements and blood
work. At each visit, data related to lipid profile, compli-
ance, and side effects were recorded. In total, patients
came for 4 visits, including visits at baseline, six, ten, and
sixteen weeks.
Statistical analysis
The hypothesis was that a combination of ezetimibe and
fenofibrate would provide equal lowering of LDL-C in
comparison with atorvastatin at low dose. With this in
mind, an absolute acceptable difference between the two
groups was deemed to be a 20% difference in LDL-C
reduction between the two groups. With a significance of
0.05 and a power of 80%, the calculation was therefore
made that 44 patients would be required for this study;
twenty-two patients would be in each arm of the study ini-
tially, and would cross-over to the other group at the half-
way mark.
The data from the study was entered into a Microsoft Excel
spreadsheet as it was obtained, and subsequently
imported into SPSS for Windows for statistical analysis.
Paired t-tests using a 95% confidence interval were used to
compare the concentrations of total cholesterol, LDL-C,
HDL-C, triglycerides and hsCRP between the two groups.
The primary outcome measure was the difference in the
percent change in LDL cholesterol over six weeks of ther-
apy in each group. A linear mixed effects model was used
to pool results over the periods of the study and estimate
the average difference between the combination and ator-
vastatin groups after adjusting for period effects. The
mixed model permitted incorporation of data from sub-
jects with only one period (arm of study) but provides
estimates identical to the classical analysis of the AB/BA
crossover study as described by Fleiss and others [20-23].
The model is efficient and unbiased but assumes no differ-
ential carryover effect. Secondary endpoints included
HDL-C, triglyceride, and hsCRP levels. The linear mixed-
effects model was used to compare all outcomes except for
hsCRP, which was compared by the non-parametric Wil-
coxon Signed-Rank test.
Further analysis was performed on serum samples in an
outside laboratory to compare apolipoprotein A and B
levels after each washout period and after each six-week
treatment. Liver enzyme levels were also drawn at each
point and analyzed by the linear mixed-effects model.
All subjects with data for at least one period were ana-
lyzed, according to the intent-to-treat principle. All tests
were two-sided and analyses were performed in SAS ver-
sion 8.2 [23].
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